Livingston P O, Ritter G, Srivastava P, Padavan M, Calves M J, Oettgen H F, Old L J
Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Cancer Res. 1989 Dec 15;49(24 Pt 1):7045-50.
The ganglioside GM2 is a differentiation antigen expressed on the cell surface of human malignant melanomas and other cancers of neuroectodermal origin. We have previously reported that immunization with purified GM2 combined with Bacillus Calmette-Guérin as adjuvant and pretreatment with low-dose cyclophosphamide induced production of antibodies against GM2 in five of six patients. We have now extended our study and analyzed the induced antibodies against GM2 were not detected. After immunization, high-titer IgM antibodies were induced in 17 of 24 patients, and high-titer IgG antibodies in eight cases. Additional treatment of 12 patients with cimetidine, a histamine H2 receptor antagonist reported to have antisuppressor cell activity, had no effect on GM2 antibody titers. Antibodies against asialo-GM2 were present in all patients, and antibodies against GM1 were present in 33% of patients, before and after immunization. Antibodies induced by immunization were specific for GM2, though some reacted predominantly with N-acetylneuraminic acid GM2 (GM2), and some reacted with GM2 and N-glycolylneuraminic acid GM2(NeuGcGM2). The pattern of reactivity with GM2 is consistent with the response to T-cell-independent antigens: both IgM and IgG antibody responses against GM2 were short lived; peak titers seen after initial and secondary vaccinations were similar; and delayed-type hypersensitivity responses to skin test challenges with GM2 were not detected in any patients. However, the IgG response typed as predominantly IgG1 and IgG3, not IgG2 as might be expected for carbohydrate antigens (which are generally T-cell-independent antigens). Because IgG1 and IgG3 antibody responses are usually to T-cell-dependent antigens, the humoral immune response elicited by GM2 vaccination has both T-cell-dependent and T-cell-independent characteristics. These IgM and IgG responses against this neuroectodermal differentiation antigen expressed on melanoma cells have been induced without evidence of neurological or other toxicity.
神经节苷脂GM2是一种分化抗原,在人类恶性黑色素瘤及其他神经外胚层起源的癌症的细胞表面表达。我们之前报道过,用纯化的GM2与卡介苗作为佐剂进行免疫,并先用低剂量环磷酰胺预处理,6名患者中有5名诱导产生了抗GM2抗体。我们现在扩展了研究,并分析了诱导产生的抗GM2抗体未被检测到的情况。免疫后,24名患者中有17名诱导产生了高滴度IgM抗体,8例产生了高滴度IgG抗体。对12名患者额外给予据报道具有抗抑制细胞活性的组胺H2受体拮抗剂西咪替丁治疗,对GM2抗体滴度没有影响。在免疫前后,所有患者体内均存在抗脱唾液酸GM2抗体,33%的患者体内存在抗GM1抗体。免疫诱导产生的抗体对GM2具有特异性,尽管有些主要与N-乙酰神经氨酸GM2(GM2)反应,有些则与GM2和N-羟乙酰神经氨酸GM2(NeuGcGM2)反应。与GM2的反应模式与对非T细胞依赖性抗原的反应一致:针对GM2的IgM和IgG抗体反应均短暂;初次和二次接种后出现的峰值滴度相似;在任何患者中均未检测到对GM2皮肤试验激发的迟发型超敏反应。然而,IgG反应主要为IgG1和IgG3型,而不是碳水化合物抗原(通常是非T细胞依赖性抗原)可能预期的IgG2型。由于IgG1和IgG3抗体反应通常针对T细胞依赖性抗原,GM2疫苗接种引发的体液免疫反应具有T细胞依赖性和非T细胞依赖性特征。这些针对黑色素瘤细胞上表达的这种神经外胚层分化抗原的IgM和IgG反应已被诱导产生,且无神经或其他毒性证据。